Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 368

1.

Deep learning for cardiovascular medicine: a practical primer.

Krittanawong C, Johnson KW, Rosenson RS, Wang Z, Aydar M, Baber U, Min JK, Tang WHW, Halperin JL, Narayan SM.

Eur Heart J. 2019 Feb 27. pii: ehz056. doi: 10.1093/eurheartj/ehz056. [Epub ahead of print]

PMID:
30815669
2.

Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.

Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM.

Circ Cardiovasc Interv. 2019 Feb;12(2):e007124. doi: 10.1161/CIRCINTERVENTIONS.118.007124.

PMID:
30704287
3.

ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine.

Bailey SR, Beckman JA, Dao TD, Misra S, Sobieszczyk PS, White CJ, Wann LS, Bailey SR, Dao T, Aronow HD, Fazel R, Gornik HL, Gray BH, Halperin JL, Hirsch AT, Jaff MR, Krishnamurthy V, Parikh SA, Reed AB, Shamoun F, Shugart RE, Yucel EK.

J Am Coll Cardiol. 2019 Jan 22;73(2):214-237. doi: 10.1016/j.jacc.2018.10.002. Epub 2018 Dec 17. No abstract available.

PMID:
30573393
4.

No conflict of interest in data monitoring.

Halperin JL.

Science. 2018 Dec 7;362(6419):1123. doi: 10.1126/science.aau9738. No abstract available.

PMID:
30523103
5.

Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.

Quinn GR, Hellkamp AS, Hankey GJ, Becker RC, Berkowitz SD, Breithardt G, Fava M, Fox KAA, Halperin JL, Mahaffey KW, Nessel CC, Patel MR, Piccini JP, Singer DE.

J Am Heart Assoc. 2018 Aug 7;7(15):e008755. doi: 10.1161/JAHA.118.008755.

6.

Three-dimensional echocardiography demonstrates a skewered left ventricular thrombus in a patient with a heart transplant.

Gannon MP, Saba SG, Hirsh BJ, Halperin JL, Garcia MJ, Pinney SP, Goldman ME.

Echocardiography. 2018 Dec;35(12):2117-2120. doi: 10.1111/echo.14158. Epub 2018 Oct 18.

PMID:
30338540
7.

US Preventive Services Task Force recommendation statement regarding screening for peripheral artery disease with the ankle-brachial index: déjà vu all over again.

Olin JW, Halperin JL.

Lancet. 2018 Sep 29;392(10153):1160-1162. doi: 10.1016/S0140-6736(18)31650-7. No abstract available.

PMID:
30303084
8.

Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF.

Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR, Melloni C.

Eur Heart J Qual Care Clin Outcomes. 2018 Sep 14. doi: 10.1093/ehjqcco/qcy040. [Epub ahead of print]

PMID:
30219887
9.

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.

Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators.

N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26.

10.

Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.

Chi G, Kerneis M, Kalayci A, Liu Y, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM.

Am Heart J. 2018 Sep;203:17-24. doi: 10.1016/j.ahj.2018.06.003. Epub 2018 Jun 13.

PMID:
30015064
11.

Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.

Chi G, Yee MK, Kalayci A, Kerneis M, AlKhalfan F, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM.

J Thromb Thrombolysis. 2018 Oct;46(3):346-350. doi: 10.1007/s11239-018-1703-5.

PMID:
29943350
12.

Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF.

Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR.

Am Heart J. 2018 Jun;200:102-109. doi: 10.1016/j.ahj.2018.02.013. Epub 2018 Feb 27.

PMID:
29898836
13.

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.

Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J, Sudworth M, Cater NB, Breazna A, Oldgren J, Kirchhof P.

Eur Heart J. 2018 Aug 21;39(32):2959-2971. doi: 10.1093/eurheartj/ehy148.

14.

Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program.

Mazurek M, Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Zint K, França LR, Lu S, Lip GYH; GLORIA-AF Investigators.

Am J Med. 2018 Aug;131(8):945-955.e3. doi: 10.1016/j.amjmed.2018.03.024. Epub 2018 Apr 11.

PMID:
29654720
15.

Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.

Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Bartels DB, Lip GYH; GLORIA-AF Investigators.

Am Heart J. 2018 Apr;198:55-63. doi: 10.1016/j.ahj.2017.08.018. Epub 2017 Aug 31.

PMID:
29653649
16.

Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.

Kerneis M, Gibson CM, Chi G, Mehran R, AlKhalfan F, Talib U, Pahlavani S, Mir M, Bode C, Halperin JL, Nafee T, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Fox KAA, Cohen M.

JACC Cardiovasc Interv. 2018 Apr 9;11(7):626-634. doi: 10.1016/j.jcin.2017.11.009. Epub 2018 Mar 14.

PMID:
29550085
17.

Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program.

McIntyre WF, Conen D, Olshansky B, Halperin JL, Hayek E, Huisman MV, Lip GYH, Lu S, Healey JS.

Clin Cardiol. 2018 Jun;41(6):744-751. doi: 10.1002/clc.22936. Epub 2018 May 10.

18.

Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF.

Barnett AS, Cyr DD, Goodman SG, Levitan BS, Yuan Z, Hankey GJ, Singer DE, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hacke W, Mahaffey KW, Nessel CC, Fox KAA, Patel MR, Piccini JP.

Int J Cardiol. 2018 Apr 15;257:78-83. doi: 10.1016/j.ijcard.2017.06.110.

PMID:
29506743
19.

Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial.

Kochar A, Hellkamp AS, Lokhnygina Y, Jones WS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Singer DE, Piccini JP, Patel MR.

Clin Cardiol. 2018 Jan;41(1):39-45. doi: 10.1002/clc.22846. Epub 2018 Feb 1.

20.

Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study.

Conti S, Reiffel JA, Gersh BJ, Kowey PR, Wachter R, Halperin JL, Kaplon RE, Pouliot E, Verma A.

J Atr Fibrillation. 2017 Feb 28;9(5):1551. doi: 10.4022/jafib.1551. eCollection 2017 Feb-Mar.

21.

Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry.

Mazurek M, Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Lip GYH; GLORIA-AF Investigators.

Thromb Haemost. 2017 Dec;117(12):2376-2388. doi: 10.1160/TH17-08-0555. Epub 2017 Dec 6.

22.

Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions.

Zafar MU, Santos-Gallego CG, Smith DA, Halperin JL, Badimon JJ.

Atherosclerosis. 2017 Nov;266:81-86. doi: 10.1016/j.atherosclerosis.2017.09.029. Epub 2017 Sep 28.

PMID:
28992468
23.

Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai.

Scott SA, Owusu Obeng A, Botton MR, Yang Y, Scott ER, Ellis SB, Wallsten R, Kaszemacher T, Zhou X, Chen R, Nicoletti P, Naik H, Kenny EE, Vega A, Waite E, Diaz GA, Dudley J, Halperin JL, Edelmann L, Kasarskis A, Hulot JS, Peter I, Bottinger EP, Hirschhorn K, Sklar P, Cho JH, Desnick RJ, Schadt EE.

Pharmacogenomics. 2017 Oct;18(15):1381-1386. doi: 10.2217/pgs-2017-0137. Epub 2017 Oct 6. Review.

24.

Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation.

Paquette M, Riou França L, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ, Zint K, Halperin JL, Huisman MV, Lip GYH, Nieuwlaat R.

J Am Coll Cardiol. 2017 Sep 26;70(13):1573-1583. doi: 10.1016/j.jacc.2017.07.793.

25.

Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR.

Am J Cardiol. 2017 Nov 15;120(10):1837-1840. doi: 10.1016/j.amjcard.2017.07.095. Epub 2017 Aug 7.

PMID:
28886856
26.

Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study.

Reiffel JA, Verma A, Kowey PR, Halperin JL, Gersh BJ, Wachter R, Pouliot E, Ziegler PD; REVEAL AF Investigators.

JAMA Cardiol. 2017 Oct 1;2(10):1120-1127. doi: 10.1001/jamacardio.2017.3180.

27.

Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).

Washam JB, Hellkamp AS, Lokhnygina Y, Piccini JP, Berkowitz SD, Nessel CC, Becker RC, Breithardt G, Fox KAA, Halperin JL, Hankey GJ, Mahaffey KW, Singer DE, Patel MR; ROCKET AF Steering Committee and Investigators.

Am J Cardiol. 2017 Aug 15;120(4):588-594. doi: 10.1016/j.amjcard.2017.05.026. Epub 2017 May 29.

PMID:
28645473
28.

Preventing Myocardial Infarction in Patients With Atrial Fibrillation: Another Piece of the Puzzle.

Halperin JL.

J Am Coll Cardiol. 2017 Jun 20;69(24):2910-2912. doi: 10.1016/j.jacc.2017.05.006. No abstract available.

29.

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.

Leef GC, Hellkamp AS, Patel MR, Becker RC, Berkowitz SD, Breithardt G, Halperin JL, Hankey GJ, Hacke W, Nessel CC, Singer DE, Fox KAA, Mahaffey KW, Piccini JP.

J Am Heart Assoc. 2017 Jun 14;6(6). pii: e004663. doi: 10.1161/JAHA.116.004663.

30.

Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Orgel R, Wojdyla D, Huberman D, Halperin JL, Breithardt G, Singer DE, Fox KAA, Hankey GJ, Mahaffey KW, Jones WS, Patel MR.

Circ Cardiovasc Qual Outcomes. 2017 May;10(5). pii: e003520. doi: 10.1161/CIRCOUTCOMES.116.003520. Review. No abstract available.

31.

2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary.

Writing Committee Members, Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FGR, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RAG, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME; ACC/AHA Task Force Members, Halperin JL, Levine GN, Al-Khatib SM, Birtcher KK, Bozkurt B, Brindis RG, Cigarroa JE, Curtis LH, Fleisher LA, Gentile F, Gidding S, Hlatky MA, Ikonomidis J, Joglar J, Pressler SJ, Wijeysundera DN.

Vasc Med. 2017 Jun;22(3):NP1-NP43. doi: 10.1177/1358863X17701592. Review. No abstract available.

PMID:
28494710
32.

Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).

Balla SR, Cyr DD, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR.

Am J Cardiol. 2017 Jun 15;119(12):1989-1996. doi: 10.1016/j.amjcard.2017.03.028. Epub 2017 Mar 29.

PMID:
28477860
33.

Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial.

Sun Y, Hu D, Stevens S, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Fox KAA, Patel MR.

Thromb Res. 2017 Aug;156:184-190. doi: 10.1016/j.thromres.2017.04.010. Epub 2017 Apr 13.

PMID:
28433206
34.

The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation.

Murphy A, Banerjee A, Breithardt G, Camm AJ, Commerford P, Freedman B, Gonzalez-Hermosillo JA, Halperin JL, Lau CP, Perel P, Xavier D, Wood D, Jouven X, Morillo CA.

Glob Heart. 2017 Dec;12(4):273-284. doi: 10.1016/j.gheart.2017.01.015. Epub 2017 Mar 21. Review.

35.

Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.

Lindner SM, Fordyce CB, Hellkamp AS, Lokhnygina Y, Piccini JP, Breithardt G, Mahaffey KW, Singer DE, Hacke W, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Becker RC, Fox KA, Patel MR; ROCKET AF Steering Committee and Investigators.

Circulation. 2017 Mar 7;135(10):1001-1003. doi: 10.1161/CIRCULATIONAHA.116.024666. No abstract available.

PMID:
28264892
36.

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.

Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, Nordio F, Mercuri MF, Antman E, Giugliano RP; ENGAGE AF-TIMI 48 Investigators.

Circulation. 2017 Mar 28;135(13):1273-1275. doi: 10.1161/CIRCULATIONAHA.116.026714. Epub 2017 Feb 16. No abstract available.

PMID:
28209729
37.

The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.

Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY; GLORIA-AF Investigators.

J Am Coll Cardiol. 2017 Feb 21;69(7):777-785. doi: 10.1016/j.jacc.2016.11.061.

38.

The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review.

Hess PL, Healey JS, Granger CB, Connolly SJ, Ziegler PD, Alexander JH, Kowey PR, Ruff CT, Flaker G, Halperin JL, Hart RG, Lopes RD.

JAMA Cardiol. 2017 Mar 1;2(3):324-331. doi: 10.1001/jamacardio.2016.5167.

PMID:
28097334
39.

When Should We Go With HALT?

Halperin JL, Zagha D.

JACC Cardiovasc Imaging. 2016 Dec 8. pii: S1936-878X(16)30893-2. doi: 10.1016/j.jcmg.2016.11.002. [Epub ahead of print] No abstract available.

41.

Low intraoperative heart rate volatility is associated with early postoperative mortality in general surgical patients: a retrospective case-control study.

Mandel-Portnoy Y, Levin MA, Bansilal S, Suprun M, Lin HM, Richardson LD, Fischer GW, Halperin JL.

J Clin Monit Comput. 2016 Dec;30(6):911-918. Epub 2015 Oct 17.

PMID:
26477036
42.

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC Jr, Halperin JL, Levine GN, Al-Khatib SM, Birtcher KK, Bozkurt B, Brindis RG, Cigarroa JE, Curtis LH, Fleisher LA, Gentile F, Gidding S, Hlatky MA, Ikonomidis JS, Joglar JA, Pressler SJ, Wijeysundera DN.

J Thorac Cardiovasc Surg. 2016 Nov;152(5):1243-1275. doi: 10.1016/j.jtcvs.2016.07.044. No abstract available.

43.

Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of IMPACT).

Lip GY, Waldo AL, Ip J, Martin DT, Bersohn MM, Choucair WK, Akar JG, Wathen M, Halperin JL; IMPACT Investigators.

Am J Cardiol. 2016 Dec 1;118(11):1680-1684. doi: 10.1016/j.amjcard.2016.08.047. Epub 2016 Aug 31.

PMID:
27665206
44.

Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.

Shah R, Hellkamp A, Lokhnygina Y, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Fox KA, Nessel CC, Mahaffey KW, Piccini JP, Singer DE, Patel MR; ROCKET AF Steering Committee Investigators.

Am Heart J. 2016 Sep;179:77-86. doi: 10.1016/j.ahj.2016.05.019. Epub 2016 Jun 22.

PMID:
27595682
45.

Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.

Ezekowitz MD, Pollack CV, Sanders P, Halperin JL, Spahr J, Cater N, Petkun W, Breazna A, Kirchhof P, Oldgren J.

Am Heart J. 2016 Sep;179:59-68. doi: 10.1016/j.ahj.2016.06.008. Epub 2016 Jun 19.

46.

Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.

Sherwood MW, Cyr DD, Jones WS, Becker RC, Berkowitz SD, Washam JB, Breithardt G, Fox KA, Halperin JL, Hankey GJ, Singer DE, Piccini JP, Nessel CC, Mahaffey KW, Patel MR.

JACC Cardiovasc Interv. 2016 Aug 22;9(16):1694-702. doi: 10.1016/j.jcin.2016.05.039.

47.

Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".

Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR.

Circulation. 2016 Jul 12;134(2):e7-8. doi: 10.1161/CIRCULATIONAHA.116.022737. No abstract available.

PMID:
27400902
48.

Updated Clinical Practice Guidelines on Heart Failure: An International Alignment.

Antman EM, Bax J, Chazal RA, Creager MA, Filippatos G, Halperin JL, Houser S, Lindenfeld J, Pinto FJ, Vardas P, Walsh MN, Williams KA, Zamorano JL.

J Card Fail. 2016 Sep;22(9):670-1. doi: 10.1016/j.cardfail.2016.07.002. Epub 2016 Jul 6. No abstract available.

PMID:
27394188
49.

A Baby in the Bathwater: Preserving Evidence-Based Medicine.

Brush JE Jr, Halperin JL.

J Am Coll Cardiol. 2016 Jul 12;68(2):214-6. doi: 10.1016/j.jacc.2016.05.023. No abstract available.

50.

Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy.

Calenda BW, Fuster V, Halperin JL, Granger CB.

Nat Rev Cardiol. 2016 Sep;13(9):549-59. doi: 10.1038/nrcardio.2016.106. Epub 2016 Jul 7. Review.

PMID:
27383079

Supplemental Content

Loading ...
Support Center